Proposal to list medical devices supplied by ResMed NZ Limited
PHARMAC is seeking feedback on a proposal to list a range of non-invasive ventilation products (“NIV Products”) in Part III of Section H of the Pharmaceutical Schedule.
What we’re proposing
PHARMAC is seeking feedback on a proposal to list a range of non-invasive ventilation products (“NIV Products”) in Part III of Section H of the Pharmaceutical Schedule from 1 September 2019, through a provisional agreement with ResMed NZ Limited (“ResMed”).
Consultation closes at 4pm on Monday, 15 July 2019 and feedback can be emailed to maree.hodgson@pharmac.govt.nz.
What would the effect be?
From 1 September 2019, ResMed’s range of NIV Products would be listed under a national agreement for all DHBs to purchase under, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreement”).
The Agreement would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of NIV Products.
The Agreement would supersede any existing DHB contracts with ResMed for the NIV Products included in the Agreement. Any NIV Products listed in the Agreement and purchased by the DHB would be at the price, and the terms and conditions stated in the Agreement, effective from the date of listing on the Pharmaceutical Schedule.
As part of the Agreement, ResMed would provide training and education that would be tailored to the needs of the individuals DHBs.
Who we think will be interested
- Suppliers and Wholesalers
- DHB Staff
- clinical staff in a range of inpatient, outpatient and community settings where NIV products are used
- respiratory and sleep clinic specialists and support personnel
- pulmonary rehabilitation specialists
- procurement and supply chain personnel
- Users of NIV products
About non-invasive ventilation (NIV) products
NIV Products are used to assist people with a wide range of airway and breathing related illnesses, that are often long-term in nature, in both hospital and community settings. Non-invasive ventilation therapy is a patient ventilation treatment that supports breathing without the need for intubation or surgical airway(external link)s, and can be delivered through positive pressure or negative pressure modalities. PHARMAC’s NIV Products category includes positive and negative pressure ventilation devices, oxygen concentration devices and respiratory gas humidifiers and their associated consumables and accessories. A wide range of clinicians and support people can be involved with these therapies, including respiratory physicians, general physicians, respiratory nurses, respiratory therapists, pulmonary rehabilitation specialists, sleep therapists, nurses across many areas, and people in the community.
Why we’re proposing this
This RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
PHARMAC has been working with suppliers who responded to the RFP to seek provisional agreements and this proposal is the latest to arise from that process. We expect to consult on further proposed agreements with suppliers of NIV Products over the coming months.
Details about our proposal
PHARMAC has entered into a provisional agreement with ResMed for their range of NIV Products. Pricing has been made available to appropriate DHB personnel.
This proposal would result in listing 169 ResMed Manufactured NIV Products on the Pharmaceutical Schedule under the following brands:
- AcuCare
- AirCurve
- Airfit
- AirSense
- AirTouch
- ClimateLineAir
- Gecko
- H4i
- HumidAir
- Lumis
- NV AcuCare
- Pixi
- ResMed
- ResScan
- RPS II
- SlimLine
- Stellar
To provide feedback
Send us an email: maree.hodgson@pharmac.govt.nz by 4pm Monday 15 July 2019.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.